Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline Review, H2 2019’, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

– The report reviews pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) therapeutics and enlists all their major and minor projects

– The report assesses Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“1st Bio Therapeutics Inc

Alterity Therapeutics Ltd

Arvinas Inc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

Corestem Inc

Denali Therapeutics Inc

EmeraMed Ltd

ICB International Inc

Inhibikase Therapeutics Inc

MitoDys Therapeutics Ltd

Modag GmbH

Neuropore Therapies Inc

Newron Pharmaceuticals SpA

ProMIS Neurosciences Inc

Stealth BioTherapeutics Corp

United Neuroscience Ltd

Voyager Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Overview

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Companies Involved in Therapeutics Development

AFFiRiS AG

Corestem Inc

Denali Therapeutics Inc

ICB International Inc

Neuropore Therapies Inc

Prana Biotechnology Ltd

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drug Profiles

Anle-138b Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-10BR05 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBT-434 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurodegenerative Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Discontinued Products

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Product Development Milestones

Featured News & Press Releases

Mar 06, 2018: PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A

Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by 1st Bio Therapeutics Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Alterity Therapeutics Ltd, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Arvinas Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Biogen Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Corestem Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Denali Therapeutics Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by EmeraMed Ltd, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by ICB International Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Inhibikase Therapeutics Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by MitoDys Therapeutics Ltd, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Modag GmbH, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Neuropore Therapies Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Newron Pharmaceuticals SpA, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by ProMIS Neurosciences Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Stealth BioTherapeutics Corp, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by United Neuroscience Ltd, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Pipeline by Voyager Therapeutics Inc, H2 2019

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Dormant Projects, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports